Kantoff PW - Search Results

1

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.

Wang X, Huang Y, Christie A, Bowden M, Lee GS, Kantoff PW, Sweeney CJ. Wang X, et al. Among authors: kantoff pw. Clin Cancer Res. 2015 Dec 15;21(24):5578-87. doi: 10.1158/1078-0432.CCR-15-0824. Epub 2015 Aug 19. Clin Cancer Res. 2015. PMID: 26289068

2

Management of hormone refractory prostate cancer: current standards and future prospects.

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.

3

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664. J Clin Oncol. 1999. PMID: 10550165 Review.

4

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Kantoff PW, et al. J Clin Oncol. 1999 Aug;17(8):2506-13. doi: 10.1200/JCO.1999.17.8.2506. J Clin Oncol. 1999. PMID: 10561316 Clinical Trial.

5

Antiandrogens in prostate cancer.

Reid P, Kantoff P, Oh W. Reid P, et al. Invest New Drugs. 1999;17(3):271-84. doi: 10.1023/a:1006344807086. Invest New Drugs. 1999. PMID: 10665479 Review.

6

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. Eder JP, et al. Among authors: kantoff pw. Clin Cancer Res. 2000 May;6(5):1632-8. Clin Cancer Res. 2000. PMID: 10815880 Clinical Trial.

7

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.

Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Kantoff PW, et al. J Clin Oncol. 2001 Jun 15;19(12):3025-8. doi: 10.1200/JCO.2001.19.12.3025. J Clin Oncol. 2001. PMID: 11408497 Clinical Trial.

8

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW; Cancer and Leukemia Group B 9480. George DJ, et al. Among authors: kantoff pw. Clin Cancer Res. 2001 Jul;7(7):1932-6. Clin Cancer Res. 2001. PMID: 11448906

9

Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.

Oh WK, George DJ, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. Cancer. 2002 Feb 1;94(3):686-9. doi: 10.1002/cncr.10269. Cancer. 2002. PMID: 11857300 Free article.

10

Chemotherapy for prostate cancer.

Gilligan T, Kantoff PW. Gilligan T, et al. Among authors: kantoff pw. Urology. 2002 Sep;60(3 Suppl 1):94-100; discussion 100. doi: 10.1016/s0090-4295(02)01583-2. Urology. 2002. PMID: 12231060 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

482 results

Search Page

Filters